blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3768305

EP3768305 - MODIFIED ONCOLYTIC ADENOVIRUSES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.10.2023
Database last updated on 14.03.2026
FormerThe patent has been granted
Status updated on  28.10.2022
FormerGrant of patent is intended
Status updated on  30.08.2022
FormerExamination is in progress
Status updated on  17.12.2021
FormerRequest for examination was made
Status updated on  25.12.2020
FormerThe international publication has been made
Status updated on  28.09.2019
Formerunknown
Status updated on  02.04.2019
Most recent event   Tooltip26.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 28.01.2026  [2026/05]
Applicant(s)For all designated states
Valo Therapeutics Oy
Cultivator 1 Viikinkaari 6
00790 Helsinki / FI
[2021/04]
Inventor(s)01 / RANKI, Tuuli
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
02 / PESONEN, Sari
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
03 / PRIHA, Petri
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
04 / YLÖSMÄKI, Erkko
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
05 / CERULLO, Vincenzo
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
06 / MARTINS, Beatriz
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
 [2021/04]
Representative(s)Myint, Julie Marie
Symbiosis IP Limited
Unit 5C
Sbarc l Spark Building
Maindy Road
Cardiff CF24 4HQ / GB
[N/P]
Former [2021/04]Myint, Julie Marie
Symbiosis IP Limited
Cardiff MediCentre
Heath Park
Cardiff CF14 4UJ / GB
Application number, filing date19712178.319.03.2019
[2021/04]
WO2019EP56768
Priority number, dateGB2018000447321.03.2018         Original published format: GB 201804473
GB2018001486713.09.2018         Original published format: GB 201814867
[2021/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019179977
Date:26.09.2019
Language:EN
[2019/39]
Type: A1 Application with search report 
No.:EP3768305
Date:27.01.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 26.09.2019 takes the place of the publication of the European patent application.
[2021/04]
Type: B1 Patent specification 
No.:EP3768305
Date:30.11.2022
Language:EN
[2022/48]
Search report(s)International search report - published on:EP26.09.2019
ClassificationIPC:A61K39/00, A61K35/761, C12N7/00, C12N15/86
[2021/04]
CPC:
C12N15/86 (EP,US); C12N7/00 (KR); A61K35/761 (EP,KR,US);
A61K39/0011 (EP,KR); A61K39/001186 (EP,KR); A61K39/001188 (EP,KR);
A61P35/00 (EP,KR,US); C07K14/70575 (EP,US); C07K14/70578 (US);
A61K2039/525 (KR); A61K2039/54 (KR); A61K2039/545 (KR);
A61K2039/6031 (EP,KR); A61K2039/80 (KR); A61K2039/876 (EP);
C12N2710/10321 (US); C12N2710/10322 (KR); C12N2710/10332 (EP,KR,US);
C12N2710/10343 (EP); C12N2710/10371 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/04]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:MODIFIZIERTE ONKOLYTISCHE ADENOVIREN[2021/04]
English:MODIFIED ONCOLYTIC ADENOVIRUSES[2021/04]
French:ADÉNOVIRUS ONCOLYTIQUES MODIFIÉS[2021/04]
Entry into regional phase23.09.2020National basic fee paid 
23.09.2020Designation fee(s) paid 
23.09.2020Examination fee paid 
Examination procedure16.08.2019Request for preliminary examination filed
International Preliminary Examining Authority: EP
23.09.2020Examination requested  [2021/04]
23.09.2020Date on which the examining division has become responsible
19.03.2021Amendment by applicant (claims and/or description)
16.12.2021Despatch of a communication from the examining division (Time limit: M02)
21.12.2021Reply to a communication from the examining division
31.08.2022Communication of intention to grant the patent
20.10.2022Fee for grant paid
20.10.2022Fee for publishing/printing paid
20.10.2022Receipt of the translation of the claim(s)
Opposition(s)31.08.2023No opposition filed within time limit [2023/45]
Fees paidRenewal fee
15.03.2021Renewal fee patent year 03
10.03.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY19.03.2019
HU19.03.2019
AL30.11.2022
AT30.11.2022
BG30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
TR30.11.2022
GR01.03.2023
IE19.03.2023
LU19.03.2023
IS30.03.2023
BE31.03.2023
PT31.03.2023
[2026/05]
Former [2025/39]CY19.03.2019
HU19.03.2019
AL30.11.2022
AT30.11.2022
BG30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IE19.03.2023
LU19.03.2023
IS30.03.2023
BE31.03.2023
PT31.03.2023
Former [2025/36]CY19.03.2019
AL30.11.2022
AT30.11.2022
BG30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IE19.03.2023
LU19.03.2023
IS30.03.2023
BE31.03.2023
PT31.03.2023
Former [2024/51]AL30.11.2022
AT30.11.2022
BG30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IE19.03.2023
LU19.03.2023
IS30.03.2023
BE31.03.2023
PT31.03.2023
Former [2024/12]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IE19.03.2023
LU19.03.2023
IS30.03.2023
BE31.03.2023
PT31.03.2023
Former [2024/08]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IE19.03.2023
LU19.03.2023
IS30.03.2023
PT31.03.2023
Former [2024/02]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
LU19.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/51]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/48]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/38]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SK30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/37]AL30.11.2022
AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/35]AT30.11.2022
EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
RO30.11.2022
RS30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/34]EE30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
RS30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/33]HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
RS30.11.2022
SM30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/25]HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
RS30.11.2022
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/23]LT30.11.2022
LV30.11.2022
GR01.03.2023
PT31.03.2023
Former [2023/22]LT30.11.2022
PT31.03.2023
Former [2023/20]LT30.11.2022
Cited inInternational search[Y] WO2014170389  (TILT BIOTHERAPEUTICS OY et al.) [Y] 1-7,11-22 * figure -; example -; claim - *
 [Y] WO2017205875  (DNATRIX INC et al.) [Y] 1-7,11-22 * example -; claim - *
 [Y] WO2018046803  (TARGOVAX OY et al.) [Y] 20,21 * example -; claim - *
 [Y]   DIACONU I ET AL: "Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus", CANCER RESEARCH, vol. 72, no. 9, 6 March 2012 (2012-03-06), pages 2327 - 2338, XP055203058, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-2975 [Y] 1-7,11-22 * abstract, figure 1, results, discussion *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
 [Y]   "Adenoviral Vectors for Gene Therapy", 1 January 2016, ELSEVIER, ISBN: 978-0-12-800276-6, article ALEMANY R: "Molecular Design of Oncolytic Adenoviruses", pages: 319 - 334, XP055585648, DOI: 10.1016/B978-0-12-800276-6.00012-7 [Y] 1-7,11-22 * introduction; page 320, first paragraph; figure 1; page 323, last paragraph - page 326, first paragraph; *

DOI:   http://dx.doi.org/10.1016/B978-0-12-800276-6.00012-7
 [Y]   ROBINSON M ET AL: "Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression", CANCER GENE THERAPY, vol. 15, no. 1, 14 September 2007 (2007-09-14), GB, pages 9 - 17, XP055587079, ISSN: 0929-1903, DOI: 10.1038/sj.cgt.7701093 [Y] 1-7,11-22 * abstract, materials and methods, figure 1, results, discussion; *

DOI:   http://dx.doi.org/10.1038/sj.cgt.7701093
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.